Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Phase 2 Study ◽

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non–Small-Cell Lung Cancer andEGFRMutations?

Journal of Clinical Oncology ◽

10.1200/jco.2013.52.8794 ◽

2014 ◽

Vol 32 (8) ◽

pp. 859-863 ◽

Cited By ~ 2

Author(s):

Eva R. Haspinger ◽

Marina Chiara Garassino ◽

Valter Torri ◽

Michela Cinquini ◽

Filippo De Braud ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis

Targeted Oncology ◽

10.1007/s11523-015-0373-x ◽

2015 ◽

Vol 11 (1) ◽

pp. 41-47 ◽

Cited By ~ 9

Author(s):

Gaetan Des Guetz ◽

Thierry Landre ◽

Bernard Uzzan ◽

Kader Chouahnia ◽

Patrick Nicolas ◽

...

Keyword(s):

Lung Cancer ◽

Survival Benefit ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials

International Journal of Cancer ◽

10.1002/ijc.27396 ◽

2012 ◽

Vol 131 (5) ◽

pp. E822-E829 ◽

Cited By ~ 78

Author(s):

Guanghui Gao ◽

Shengxiang Ren ◽

Aiwu Li ◽

Jianfang Xu ◽

Qinghua Xu ◽

...

Keyword(s):

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Randomized Controlled ◽

Interstitial Lung Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Carcinoma

Clinical Lung Cancer ◽

10.3816/clc.2006.s.011 ◽

2006 ◽

Vol 8 ◽

pp. S31-S35 ◽

Cited By ~ 15

Author(s):

Ken Y. Yoneda ◽

Kimberly A. Hardin ◽

David R. Gandara ◽

David K. Shelton

Keyword(s):

Epidermal Growth Factor Receptor ◽

Kinase Inhibitor ◽

Small Cell Lung Carcinoma ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation

Lung Cancer ◽

10.1016/j.lungcan.2018.12.007 ◽

2019 ◽

Vol 128 ◽

pp. 6-12 ◽

Cited By ~ 5

Author(s):

Xiangtao Yan ◽

Huijuan Wang ◽

Peng Li ◽

Guowei Zhang ◽

Mina Zhang ◽

...

Keyword(s):

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Egfr Tki ◽

First Line Treatment

Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000597 ◽

2015 ◽

Vol 10 (8) ◽

pp. e81-e82

Author(s):

Young Hak Kim ◽

Michiaki Mishima

Keyword(s):

Lung Cancer ◽

Maintenance Treatment ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Line Chemotherapy

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases

Chronic Diseases and Translational Medicine ◽

10.1016/j.cdtm.2017.11.001 ◽

2017 ◽

Vol 3 (4) ◽

pp. 221-229 ◽

Cited By ~ 1

Author(s):

Ling-Ling Kong ◽

Lin-Lin Wang ◽

Li-Gang Xing ◽

Jin-Ming Yu

Keyword(s):

Lung Cancer ◽

Clinical Trials ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-06-0261 ◽

2006 ◽

Vol 12 (12) ◽

pp. 3652-3656 ◽

Cited By ~ 52

Author(s):

Paul A. Bunn ◽

Rafal Dziadziuszko ◽

Marileila Varella-Garcia ◽

Wilbur A. Franklin ◽

Samir E. Witta ◽

...

Keyword(s):

Lung Cancer ◽

Lung Cancer Patient ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Selection For

PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy

Bioorganic & Medicinal Chemistry ◽

10.1016/j.bmc.2018.02.007 ◽

2018 ◽

Vol 26 (8) ◽

pp. 1609-1613 ◽

Cited By ~ 3

Author(s):

Akira Makino ◽

Anna Miyazaki ◽

Ayaka Tomoike ◽

Hiroyuki Kimura ◽

Kenji Arimitsu ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e21073 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e21073-e21073 ◽

Cited By ~ 3

Author(s):

Morihito Okada ◽

Kentaro Tanaka ◽

Hajime Asahina ◽

Taishi Harada ◽

Kosuke Hamai ◽

...

Keyword(s):

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Egfr Tyrosine Kinase Inhibitor ◽

T790m Mutation ◽

Phase 2 Study ◽